Jessica JohnsonThe A24 documentary You Can See Everything premiered to universal acclaim at the Telluride Film Festival on September 6, 2026 — earning 100% on Rotten Tomatoes and a 95/100 score on Metacritic. Directed by Nathan Fielder and Lance Oppenheim, the 174-minute film follows Elizabeth Holmes, founder of the collapsed blood-testing company Theranos, in the weeks before she reported to federal prison. But beneath the gripping portrait of a convicted fraudster lies a cautionary legal tale with hard numbers attached: more than $700 million raised from investors, $452 million in court-ordered restitution, and hundreds of people who had no idea they were being deceived until it was far too late.
Why the Holmes Case Still Resonates in 2026
The film arrives as Holmes's legal saga refuses to fully close. In February 2025, the Ninth Circuit Court of Appeals upheld her conviction on four federal counts — one count of conspiracy to commit wire fraud against investors and three counts of wire fraud on individual investors — after she had appealed the original verdict. In March 2026, her 135-month sentence was reduced by one year, but she remains incarcerated at the Federal Prison Camp in Bryan, Texas, a minimum-security facility.
The rise and fall of Theranos is documented in exhaustive detail by the U.S. Department of Justice. At Theranos's peak, the company was valued at $9 billion on the promise of a proprietary device called the "Edison" that was supposed to run hundreds of blood tests from a single finger-prick of blood faster, cheaper, and more accurately than traditional labs. The problem: the technology didn't work. Pharmaceutical companies that evaluated the device found it couldn't replicate results. Holmes continued raising money and projecting success even as the company burned through its remaining cash.
The total investor losses in wire transfers connected to Holmes's convictions exceeded $140 million. Court-ordered restitution of $452 million included $125 million owed to media mogul Rupert Murdoch, with other major victims including investors connected to the DeVos and Walton families.
What Legal Experts Say About Investment Fraud Today
The Theranos case is a textbook example of what securities attorneys call "material misrepresentation" — when a company executive makes false or misleading statements about a product, technology, or financial performance that a reasonable investor would consider important before committing funds.
Under 18 U.S.C. § 1343, federal wire fraud charges apply when someone uses electronic communications — emails, investor decks, video calls, wire transfers — to execute a scheme to defraud. Holmes was convicted precisely because of emails and presentations she sent to investors that contained statements she knew to be false.
But this isn't only a story about billionaires losing large sums. Individual investors in private startups, crowdfunding rounds, or angel deals may have legal recourse under the same framework when:
- A founder misrepresented the company's product, technology, or regulatory status in written materials
- Investment funds were used for purposes not disclosed in the offering documents
- You were denied access to audited financial statements before signing
- Due diligence requests were deflected or met with broad NDAs instead of documentation
Understanding where fraud ends and business failure begins is the central question in these cases — and it requires legal analysis to answer correctly.
Concrete Case: The $150,000 Angel Round That Fell Apart
Consider a scenario that plays out regularly in 2026's startup ecosystem. A first-time angel investor commits $150,000 to a health-tech startup in early 2025. The CEO presents a proprietary AI diagnostic platform she claims has been "validated" by two hospital systems and is awaiting FDA 510(k) clearance. The investor signs an NDA, reviews a 30-slide pitch deck, and wires the funds without independently verifying the hospital partnership claims or the regulatory timeline.
By mid-2026, the company enters voluntary dissolution. The CEO later acknowledges the hospital "validation" was a 90-day paid pilot program — not a clinical endorsement — and that the FDA clearance application had not yet been filed at the time of the investment.
The if/then analysis an attorney would apply:
- If the investor can show that the CEO knew the hospital validation claim was materially false at the time it was made (i.e., it wasn't a puffed-up projection but a deliberate misstatement), then there is a basis for a civil wire fraud claim, since the pitch deck was emailed — an electronic communication — and the funds were transferred by wire.
- If multiple investors collectively lost $1 million or more in the same round, then the case may cross the threshold for a federal securities fraud investigation and potential SEC referral.
- If the investor retained screenshots, PDFs of the pitch deck, and email threads with the CEO's representations, then those materials become primary evidence in civil litigation for compensatory damages — potentially recovering the full $150,000 plus attorneys' fees under fraud statutes.
One critical legal nuance: federal civil fraud claims have a five-year statute of limitations under 18 U.S.C. § 1658. The clock typically starts not when the investor discovers the fraud but when the last fraudulent act occurred. This gap — between when you find out and when the law considers the fraud to have happened — is precisely why consulting an attorney early matters. Waiting 18 months to act after discovering the misrepresentation can leave you outside the window for recovery.
You can read more about how wire fraud charges work in similar cases in our coverage of the Detroit pandemic fraud prosecution and what it means for federal fraud victims in 2026.
The Warning Signs Holmes's Investors Missed
Securities attorneys who have analyzed the Theranos case have identified recurring red flags that apply directly to private investment decisions in 2026:
Proprietary technology no one can independently test. Holmes prohibited investors from auditing the Edison device, citing trade secrets. Legitimate companies with working technology welcome technical due diligence because the results support, not undermine, the pitch.
Blanket NDAs in place of documentation. When every question about core technology, revenue projections, or regulatory status is answered with a confidentiality agreement rather than a verifiable document, that's a structural warning sign — not standard practice.
Celebrity or prestige investors as the primary proof of concept. Theranos's board included George Shultz, James Mattis, and other high-profile figures. Their presence communicated legitimacy but said nothing about whether the product worked. Prestige is social proof that can be engineered.
Vague regulatory language. Holmes told investors the Edison had "FDA approval" when the company held only limited clearance for a single test — out of hundreds it was running commercially. "FDA-approved," "FDA-cleared," and "FDA-authorized" are legally distinct terms that founders sometimes blur deliberately.
If you spot any of these warning signs — in a startup pitch, a private placement memorandum, or an ongoing investment relationship — document everything immediately. Screenshots of pitch materials, email threads containing representations about the company, and wire transfer confirmations all become evidence if fraud is later confirmed.
For investors who have already been through a similar experience, our coverage of online fundraiser fraud and your legal rights in 2026 explains the range of civil remedies available.
What to Do If You Suspect You Were Defrauded
The window to act matters enormously in investment fraud cases. If you are a current or former investor who believes you received materially false information before committing funds to a startup or private company, you have options — but exercising them requires legal expertise.
A securities and investment fraud attorney can:
- Review your investment documents and pitch materials for actionable misrepresentation claims
- Assess whether your individual losses or the total round size meets federal civil fraud thresholds
- Help file a complaint with the SEC's Office of the Whistleblower or the FBI if criminal referral is appropriate
- Represent you in civil litigation or arbitration against the founders or fund managers
You Can See Everything opens in theaters on October 16, 2026. The film's gift is intimacy — a rare, unsettling look at one of America's most notorious white-collar criminals before and during her prison sentence. What it cannot show are the countless smaller-scale versions of the Theranos story that never reach Telluride, never attract A24, and often end with individual investors absorbing losses quietly because they didn't know where to start.
If you believe you've been the victim of startup investment fraud, a consultation with a securities attorney is the right first step — before the statute of limitations clock runs out.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. Every situation is different — consult a qualified attorney for guidance specific to your circumstances.
